Abstract. At present, molecular markers of colorectal cancer (CRC), including KRAS, NRAS and BRAF mutations, and the microsatellite status are evaluated for the development of personalized treatments. However, clinicopathological and molecular characteristics and the prognostic role of NRAS mutations remain unclear. In the present study, a total of 1,304 consecutive stage 0-IV CRC tumor samples were analyzed for KRAS (exon 2, 3 and 4), NRAS (exon 2 and 3) and BRAF (exon 15) mutations. Multivariate analysis was performed to assess the prognostic impact of NRAS mutations. KRAS, NRAS and BRAF mutations were identified in 553 (42.4%), 35 (2.7%), and 59 (4.5%) of 1,304 CRC cases, respectively. Tumors with NRAS mutations were more frequently located in the distal colorectum compared with those with KRAS or BRAF mutations. Multivariate analysis indicated that KRAS and BRAF mutations were found to be associated with poor prognosis [hazard ratio (HR)=1.44, 95% confidence interval (CI), 95% CI, respectively], whereas NRAS mutations were associated with a trend toward favorable prognosis (HR= 0.53; 95% CI, 0.27-1.03). Characteristics and prognosis of CRC with NRAS mutations are different from those with KRAS or BRAF mutations.
Introduction
The epidermal growth factor receptor (EGFR) is one of the most important molecular targets for advanced colorectal cancer. Activation of this transmembrane receptor tyrosine kinase stimulates signaling pathways supporting cell proliferation, adhesion, migration, evasion of apoptosis, angiogenesis and survival (1) (2) (3) . Oncogenic signaling pathways downstream of EGFR, including RAS/Raf/MAPK and PI3K/PTEN/Akt pathways, are important mechanisms of tumor progression.
Activating mutations in the RAS oncogene family are present in ~30% of all human cancers. RAS genes encode highly homologous proteins: KRAS, NRAS and HRAS (4) . Mutations in the KRAS gene are frequency reported in various human neoplasms, including pancreatic cancer, biliary tract cancer and lung adenocarcinoma (4) (5) (6) . Cancer types with a high rate of NRAS mutations include myeloid leukemia and cutaneous melanoma, whereas HRAS mutations are typical of bladder and cervical cancers (4, 7, 8) . In colorectal cancer (CRC), rates of KRAS, NRAS and HRAS mutation are 30-42%, 2.2-5% and 0-0.8%, respectively (9) (10) (11) (12) (13) (14) . Relatively low rates of NRAS and HRAS mutations in CRC remain unexplained.
Anti-EGFR antibody therapy exhibits antitumor effects by inhibiting multiple EGFR signaling pathways, including RAS/RAF/MAPK and PI3K/PTEN/AKT pathways. Clinical trials have demonstrated that anti-EGFR monoclonal antibodies (i.e., cetuximab or panitumumab) are largely ineffective for metastatic CRC patients when tumors harbor mutations in the codon 12 or 13 of KRAS exon 2 (15) (16) (17) (18) (19) (20) . These mutations cause constitutive activation of the RAS/RAF/MAPK pathway, regardless of EGFR inhibition. Therefore, KRAS exon 2 mutations are recognized as predictive markers of anti-EGFR therapy resistance for metastatic CRC patients. Accordingly, these clinical trials routinely exclude CRC patients harboring KRAS exon 2 mutations.
Recent studies suggest that other activating mutations in KRAS or NRAS, in addition to KRAS exon 2, confer resistance to anti-EGFR therapy (9, 11, 13, 21) . Since KRAS and NRAS mutations tend to be mutually exclusive, they may be present in approximately half of metastatic CRC patients (9) (10) (11) (12) (13) (14) . Therefore, personalized cancer therapy should be tailored to the KRAS and NRAS mutation profile of each patient to improve treatment outcomes.
Previous studies have evaluated the clinicopathological features and prognostic influence of KRAS or BRAF mutations in colorectal cancer. The prognostic value of KRAS mutations in CRC remains controversial (22) (23) (24) 
Materials and methods
Patients and tissue samples. The present study was conducted on 1,304 consecutive primary CRC patients at the Saitama Cancer Center from July 1999 to July 2008. Information on clinical data, including age at diagnosis, gender, tumor size, histological differentiation, tumor location, International Union against Cancer (UICC) stage and prognosis were collected from medical records. Tissue samples were surgically excised after obtaining informed consent from each patient. All tumor tissues were paired with normal colorectal tissues and immediately stored at -80˚C. The present study was approved by the Ethics Committee of the Saitama Cancer Center.
Mutation analysis of KRAS, BRAF and NRAS.
Genomic DNA from each sample was extracted by standard SDS-proteinase K procedure, followed by ethanol precipitation. All tumor samples were tested for KRAS exon 2, 3 and 4; BRAF exon 15 (codon 600); NRAS exon 2 and 3; and MSI status.
KRAS mutations in exon 2 and 3 were detected by denaturing gradient gel electrophoresis (DGGE), and BRAF mutations in exon 15 by PCR-restriction fragment length polymorphism (RFLP), as previously described (28, 29) .
High resolution melting (HRM) analysis was used to identify mutations in NRAS exon 2 and 3 and in KRAS exon 4 using a Rotor-Gene Q (Qiagen, Hilden, Germany). Primer sets for NRAS were as follows: exon 2, 5'-GGTTTCCAACAGGT TCTTGC-3' (forward) and 5'-CACTGGGCCTCACCTCTA TG-3' (reverse); exon 3, 5'-CACACCCCCAGGATTCTTAC-3' (forward) and 5'-TGGCAAATACACAGAGGAAGC-3' (reverse). The primer set for KRAS exon 4 was as follows: 5'-GCCTTCTAGAACAGTAGACAC-3' (forward) and 5'-GA CATAACAGTTATGATTTTGCAGA-3' (reverse). The reaction mixture contained 7 µl of 2X LightCycler 480 High Resolution Melting Master Reaction Mix (Roche Diagnostics, Mannheim, Germany) with 0.21 µM of each forward and reverse primer, 3.2 mM MgCl 2 , 20 ng purified genomic DNA, and water to a total volume of 14 µl. PCR cycling and melting conditions were as follows: initial denaturation at 95˚C for 5 min, followed by 40 cycles of 10 sec at 95˚C, 20 sec at 57˚C, and 10 sec at 72˚C. One heteroduplex cycle was performed at 95˚C for 1 min and 40°C for 1 min, followed by melting from 72˚C to 95˚C with 10 acquisitions per ˚C. HRM data were analyzed using the Rotor-Gene Q software ver.2.0.2.4.
The DNA sequence of NRAS exon 2 and 3 mutations was determined by HRM using primers particularly designed for HRM. Amplified products were labeled with GenomeLab™DTCS Quick Start kit (Beckman Coulter Inc., Fullerton, CA, USA) according to the manufacturer's instructions and sequenced using the GenomeLab™ GeXP Genetic Analysis System (Beckman Coulter). Sequencing was performed in both directions, and sequence analysis was performed using the GenomeLab Genetic Analysis System v10.2 (Beckman Coulter).
Analysis of microsatellite status. The MSI status was determined using Bethesda markers: BAT25, BAT26, D5S346, D2S123 and D17S250. PCR and subsequent analyses were performed as previously described (30) . CRC samples showing instability in two or more markers were defined as microsatellite instability-high (MSI-H), and the ones with none or one marker as microsatellite stable (MSS).
Statistical analysis.
Possible associations between each mutation and clinicopathological parameters of CRC were assessed by the Chi-square or Fisher's exact test for categorical variables and Mann-Whitney U or Kruskal-Wallis test for continuous variables. Overall survival (OS) time was calculated from the date of surgery to the date of death by any cause or censored at the last follow-up visit. Cox proportional hazards analysis was used to estimate clinicopathological-and biomarker-specific survival hazard ratios (HRs) and 95% confidence intervals (CIs). A multivariable model stratification by UICC stage was performed. All P-values were calculated from two-sided test, and P-values <0.05 were considered statistically significant. All statistical analyses were performed with the SPSS Statistics v.20 (SPSS, Inc., Chicago, IL, USA).
Results
Patient characteristics. All 1,304 patients enrolled in the present study were diagnosed with either CRC stage 0 (n=48), stage I (n=248), stage II (n=407), stage III (n=384) or stage IV (n=217) ( Table I) . Three hundred and seventy-nine cancers were from the proximal colon (cecum to transverse colon), 544 from the distal colon (descending colon to sigmoid colon) and 381 from the rectum. The median follow-up period was 5.6 years (interquartile range, 4.1-7.8 years), during which there were 435 deaths (33%).
Frequency of KRAS, NRAS and BRAF mutations. All 1,304
CRC cases were examined for mutations in KRAS (exon 2, 3 and 4), NRAS (exon 2 and 3) and BRAF (exon 15), as well as MSI status and clinicopathological factors (Table I) . KRAS mutations were detected in 42.4% (n=553), NRAS in 2.7% (n=35) and BRAF in 4.5% (n=59) of patients. MSI-H was detected in 5.5% (n=72) of cases. Table II presents changes in the nucleotides and corresponding amino acids detected in NRAS, with p.G12D (codon 12), p.G13R (codon 13) and p.Q61K (codon 61) as the most frequently noted mutations.
Mapping associations between molecular markers revealed that 3 patients had both KRAS and NRAS mutations, whereas 1 patient had both KRAS and BRAF mutations (Fig. 1) . KRAS/NRAS mutation combinations were as follows: p.G12D/p.V9A, pG12V/p.R68S and p.G57T/p.G13D. In contrast, NRAS and BRAF mutations were mutually exclusive. Regarding the MRI status, 28 patients with KRAS mutations also had MSI-H tumors compared with 23 patients with BRAF mutations. None of the patients with NRAS mutations had MSI-H tumors.
BRAF mutations were significantly more frequent in MSI-H than in MSS tumors (P<0.001), whereas no significant association was observed between MSI status and KRAS or NRAS mutations. 
Discussion
The present study investigated clinicopathological and prognostic features of KRAS, NRAS and BRAF mutations in tumors from 1,304 consecutive CRC patients. An important finding was that patients undergoing CRC tumor resection at all stages were targeted by all these mutations. In addition, to the best of our knowledge, this is the first large study to present statistically significant comparisons between these three categories of RAS/RAF mutations in CRC patients.
NRAS mutations were observed in 35 (2.7%) of the 1,304 patients, of which 20 (1.5%) patients revealed a mutation in exon 2 and others (1.2%) in exon 3. These data are consistent with previous studies that reported NRAS mutations in 2.2-5.0% of CRC tumors, with approximately equal frequency in exon 2 and 3 (9, 10, 12, 29) . Moreover, we showed that NRAS mutations are detected in early stages of CRC and tend to occur more frequently in stage IV cancers than in stage 0-III cancers. Therefore, NRAS mutations appear to be acquired at early and advanced stages of CRC (31) . Nonetheless, the tendency of higher NRAS mutation rates in stage IV CRC should be ascertained in a larger scale study. The frequency of KRAS mutations was also compatible with previous studies, but the frequency of BRAF mutations (4.5%) declined below 7.4-10.1% of the values previously reported (10, 13, 14) . On the other hand, Yokota et al (32) reported an incidence of 4.7% for BRAF mutations (15/319 patients) in Japanese CRC patients. Such agreement with our Japanese study suggests that racial Table III . Mutation rates of KRAS and NRAS genes for each exon.
Gene
Patients with mutations, n (%) or environmental factors may affect the frequency of BRAF mutations. The strong overlap between BRAF mutation and MSI-H status that we detected suggests that the low frequency in the BRAF mutation is affected by the low MSI-H frequency reported among Asians compared with Westerners (33) .
KRAS
In the present study, 3 cases of 1,304 had mutations in both KRAS and NRAS, which is inconsistent with previous reports of mutual exclusivity. Notably, all three tumors presented rare mutations (NRAS p.V9A, NRAS p.R68S and KRAS p.G57T), whereas these tumors had common mutations (KRAS p.G12D, KRAS p.G12V and NRAS p.G13D). The oncogenic activity of these minor mutations is unknown, except for KRAS p.G57T (28) . Therefore, KRAS and NRAS mutation detection only in major mutation lesion may have missed these rare mutations. Table IV . Clinicopathological characteristics according to the KRAS, NRAS and BRAF mutation status. Colorectal tumors with NRAS mutations were found more frequently in the distal colon and rectum compared with tumors with KRAS or BRAF mutations, while the distribution of BRAFmutated tumors was consistent with previous studies reporting that BRAFmutated tumors are primarily located in the proximal colon (22, 32, 34) . It was proposed that cellular transformation and mutations occur more frequently in the proximal colon due to close contact of epithelial cells with stimulating bowel content (34) . However, this theory does not explain the higher frequency of NRASmutated tumors in the distal colon and rectum compared with those with KRAS or BRAF mutations. Elucidating factors responsible for distinct locations of KRAS-and NRAS-mutated tumors may be crucial to our understanding of NRAS mutations in CRC patients.
The prognosis of advanced CRC patients carrying NRAS mutations has been reported in the form of subset analysis of clinical studies using anti-EGFR drugs such as cetuximab and panitumumab (9, 13, 14) . Although there is currently no consistent view regarding the efficacy of anti-EGFR drugs for CRC patients with NRAS mutations, several reports consider this form of therapy inappropriate for such CRC patients. However, the fundamental malignant potential of the NRAS mutation should be considered to determine the efficacy of anti-EGFR drugs. To the best of our knowledge, this is the first study to compare patient survival in NRAS-mutated and triple wild-type CRCs. Numerous studies report an association between BRAF mutations and poor clinical outcome (15, 22, 23, 27, 32, 35) . Although the prognostic value of the KRAS mutation is still controversial, several studies suggest a poor prognosis (24, 35, 36) . Since NRAS is a RAS family member, we expected NRAS-mutated CRC patients to have a poor prognosis compared with those without RAS mutations. However, multivariate analysis showed a tendency toward a better prognosis for NRAS-mutated CRC patients. Therefore, the present study suggests that CRC cases with NRAS mutations exhibit different characteristics than CRC cases with KRAS mutations.
Recent studies report that common KRAS exon 2 mutations targeting the RAS/RAF/MAPK pathway are currently used to determine patient eligibility for anti-EGFR monoclonal antibody therapy (19, 37, 38) . Minor mutations (KRAS exon 3 and 4, NRAS, BRAF) are expected to become the next predictive biomarkers. In fact, a recent clinical trial on anti-EGFR monoclonal antibodies excluded patients with the KRAS exon 2 mutation and those with these less frequent mutations (39) . In the present study, the incidence of KRAS exon 2 mutations was 38%, whereas the combined mutation rate for KRAS exon 3 and 4, NRAS and BRAF was 49.3%. For stage IV CRC patients subjected to anti-EGFR monoclonal antibody therapy, the total mutation rate increased from 37.3 to 51.6%. If the validity of excluding CRC patients with these minor RAS mutations from anti-EGFR monoclonal antibody therapy is verified by future trials, more than 50% of CRC patients would greatly benefit from personalized medicine for enhanced efficacy and a better prognosis.
In conclusion, the present study demonstrated that KRAS-and NRAS-mutated CRC tumors exhibit distinct characteristics and distributions along the colorectum. Future molecular biology studies should address the significance of these differences between NRAS-and KRAS-mutated CRC and confirm possible positive prognoses associated with NRAS mutations. 
